Please amend the claims as follows:

1. (Withdrawn) A method of treating a female subject suffering from an Androgen Deficiency in Female (ADIF)-associated condition, said method comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound, in an amount effective to treat said ADIF-associated condition.

2. (Withdrawn) The method of claim 1, wherein said method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of said SARM compound, or any combination thereof.

3. (Withdrawn) The method according to claim 1, wherein said SARM compound is represented by the structure of formula I:



I

wherein G is O or S;

X is a bond, O, CH_2, NH, Se, PR, NO or NR;

T is OH, OR, -$NHCOCH_3$, or NHCOR

Z is NO_2, CN, COOH, COR, NHCOR or CONHR;

Y is CF_3, F, I, Br, Cl, CN, CR_3 or SnR_3;

Q is alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH; and

R_1 is CH_3, CH_2F, CHF_2, CF_3, CH_2CH_3, or CF_2CF_3.

4. (Withdrawn) The method according to claim 1, wherein said SARM compound is represented by the structure of formula II.



II

wherein X is a bond, O, CH_2, NH, Se, PR, NO or NR;

Z is NO_2, CN, COOH, COR, NHCOR or CONHR;

Y is CF_3, F, I, Br, Cl, CN, CR_3 or SnR_3;

Q is alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH.

5. (Withdrawn) The method according to claim 1, wherein said SARM compound is represented by the structure of formula III.



III

wherein X is a bond, O, CH_2, NH, Se, PR, NO or NR;

G is O or S;

R_1 is CH_3, CH_2F, CHF_2, CF_3, CH_2CH_3, or CF_2CF_3;

T is OH, OR, -$NHCOCH_3$, or NHCOR;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH;

A is a ring selected from:



B is a ring selected from:



wherein A and B cannot simultaneously be a benzene ring;

Z is NO_2, CN, COOH, COR, NHCOR or CONHR;

Y is CF_3, F, I, Br, Cl, CN CR_3 or SnR_3;

Q_1 and Q_2 are independently of each other a hydrogen, alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R, SR,



Q_3 and Q_4 are independently of each other a hydrogen, alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R or SR;

W_1 is O, NH, NR, NO or S; and

W_2 is N or NO.

6. (Withdrawn) The method according to claim 1, wherein said SARM compound is represented by the structure of formula IV:



IV

wherein X is a bond, O, CH_2, NH, Se, PR, NO or NR;

G is O or S;

T is OH, OR, -$NHCOCH_3$, or NHCOR;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH;

R_1 is CH_3, CH_2F, CHF_2, CF_3, CH_2CH_3, or CF_2CF_3;

R_2 is F, Cl, Br, I, CH_3, CF_3, OH, CN, NO_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, alkyl, arylalkyl, OR, NH_2, NHR, NR_2, SR;

R_3 is F, Cl, Br, I, CN, NO_2, COR, COOH, CONHR, CF_3, SnR_3, or R_3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:



Z is NO_2, CN, COR, COOH, or CONHR;

Y is CF_3, F, Br, Cl, I, CN, or SnR_3;

Q is H, alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OH, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

n is an integer of 1-4; and

m is an integer of 1-3.

7. (Withdrawn) The method according to claim 1, wherein said SARM compound is represented by the structure of formula V:



V

wherein

R_2 is F, Cl, Br, I, CH_3, CF_3, OH, CN, NO_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, alkyl, arylalkyl, OR, NH_2, NHR, NR_2, SR;

R_3 is F, Cl, Br, I, CN, NO_2, COR, COOH, CONHR, CF_3, SnR_3, or R_3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:



R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH;

Z is NO_2, CN, COR, COOH, or CONHR;

Y is CF_3, F, Br, Cl, I, CN, or SnR_3;

Q is H, alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OH, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



n is an integer of 1-4; and

m is an integer of 1-3.

8. (Withdrawn) The method according to claim 1, wherein said SARM compound is represented by the structure of formula VI.



VI

9.-13. Cancelled

14. (Withdrawn) The method of claim 1, wherein the SARM is an androgen receptor agonist.

15. (Withdrawn) The method of claim 1, wherein the SARM has in-vivo androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor.

16. (Withdrawn) The method of claim 1, wherein the SARM is an androgen receptor antagonist.

17. (Withdrawn) The method of claim 1, wherein said SARM has an agonistic effect muscle or bone.

18. (Withdrawn) The method of claim 1, wherein said SARM has no effect on muscle or bone.

19. (Withdrawn) The method of claim 1, wherein said SARM penetrates the central nervous system (CNS).

20. (Withdrawn) The method of claim 1, wherein said SARM does not penetrate the central nervous system (CNS).

21. (Withdrawn) The method according to claim 1, wherein said administering comprises administering a pharmaceutical preparation comprising said SARM and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph, prodrug, or any combination thereof; and a pharmaceutically acceptable carrier.

22. (Withdrawn) The method according to claim 21, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical preparation in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical preparation; orally administering to said subject said pharmaceutical preparation in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical preparation.

23. (Withdrawn) The method according to claim 21 wherein said pharmaceutical preparation is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.

24. (Withdrawn) The method of claim 1, wherein said ADIF-associated condition is sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia,

osteoporosis, alterations in cognition and mood, fatigue, depression, anemia, muscle weakness, hair loss, obesity, polycystic ovarian disease, endometriosis, breast cancer, uterine cancer, ovarian cancer, or any combination thereof.

25. (Withdrawn) The method of claim 1, wherein said female subject is an aging female subject.

26. (Original) A method of preventing, suppressing, inhibiting or reducing the incidence of an Androgen Deficiency in Female (ADIF)-associated condition in a female subject, said method comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound, in an amount effective to prevent, suppress, inhibit or reduce the incidence of said ADIF-condition.

27. (Original) The method of claim 26, wherein said method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of said SARM compound, or any combination thereof.

28. (Currently Amended) The method according to claim 26, wherein said SARM compound is represented by the structure of formula I:



I

wherein G is O or S;

X is a bond, O, CH_2, NH, Se, PR, NO or NR;

T is OH, OR, -$NHCOCH_3$, or NHCOR

Z is NO_2, CN, COOH, COR, NHCOR or CONHR;

Y is CF_3, F, I, Br, Cl, CN, CR_3 or SnR_3;

Q is alkyl, halogen, CF_3, CN, CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R, SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH; and

R_1 is CH_3, CH_2F, CHF_2, CF_3, CH_2CH_3, or CF_2CF_3.

29. (Currently Amended) The method according to claim 26, wherein said SARM compound is represented by the structure of formula II.



II

wherein X is a bond, O, CH_2, NH, Se, PR, NO or NR;

Z is NO_2, CN, COOH, COR, NHCOR or CONHR;

Y is CF_3, F, I, Br, Cl, CN, CR_3 or SnR_3;

Q is alkyl, halogen, CF_3, CN, CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH.

30. (Currently Amended) The method according to claim 26, wherein said SARM compound is represented by the structure of formula III.



III

wherein X is a bond, O, CH_2, NH, Se, PR, NO or NR;

G is O or S;

R_1 is CH_3, CH_2F, CHF_2, CF_3, CH_2CH_3, or CF_2CF_3;

T is OH, OR, -$NHCOCH_3$, or NHCOR;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH;

A is a ring selected from:



B is a ring selected from:



wherein A and B cannot simultaneously be a benzene ring;

Z is NO_2, CN, COOH, COR, NHCOR or CONHR;

Y is CF_3, F, I, Br, Cl, CN CR_3 or SnR_3;

Q_1 and Q_2 are independently of each other a hydrogen, alkyl, halogen, CF_3, CN_2 CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R, SR,



Q_3 and Q_4 are independently of each other a hydrogen, alkyl, halogen, CF_3, CN_2 CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R or SR;

W_1 is O, NH, NR, NO or S; and

W_2 is N or NO.

31. (Currently Amended) The method according to claim 26, wherein said SARM compound is represented by the structure of formula IV:



IV

wherein X is a bond, O, CH_2, NH, Se, PR, NO or NR;

G is O or S;

T is OH, OR, -$NHCOCH_3$, or NHCOR;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH;

R_1 is CH_3, CH_2F, CHF_2, CF_3, CH_2CH_3, or CF_2CF_3;

R_2 is F, Cl, Br, I, CH_3, CF_3, OH, CN, NO_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, alkyl, arylalkyl, OR, NH_2, NHR, NR_2, SR;

R_3 is F, Cl, Br, I, CN, NO_2, COR, COOH, CONHR, CF_3, SnR_3, or R_3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:



Z is NO_2, CN, COR, COOH, or CONHR;

Y is CF_3, F, Br, Cl, I, CN, or SnR_3;

Q is H, alkyl, halogen, CF_3, CN, CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OH, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

n is an integer of 1-4; and

m is an integer of 1-3.

32. (Currently Amended) The method according to claim 26, wherein said SARM

compound is represented by the structure of formula V:



V

wherein

R_2 is F, Cl, Br, I, CH_3, CF_3, OH, CN, NO_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, alkyl, arylalkyl, OR, NH_2, NHR, NR_2, SR;

R_3 is F, Cl, Br, I, CN, NO_2, COR, COOH, CONHR, CF_3, SnR_3, or R_3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:



R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH;

Z is NO_2, CN, COR, COOH, or CONHR;

Y is CF_3, F, Br, Cl, I, CN, or SnR_3;

Q is H, alkyl, halogen, CF_3, CN, CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OH, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

n is an integer of 1-4; and

m is an integer of 1-3.

33. (Original) The method according to claim 26, wherein said SARM compound is represented by the structure of formula VI.



VI

34. (Original) The method according to claim 26, wherein said SARM compound is represented by the structure of formula VII.



VII

35. (Original) The method according to claim 26, wherein said SARM compound is represented by the structure of formula VIII.



VIII

36. (Original) The method according to claim 26, wherein said SARM compound is represented by the structure of formula IX.



IX

37. (Original) The method according to claim 26, wherein said SARM compound is represented by the structure of formula X.



X

38. (Original) The method according to claim 26, wherein said SARM compound is represented by the structure of formula XI.



XI

39. (Original) The method of claim 26, wherein the SARM is an androgen receptor agonist.
40. (Original) The method of claim 26, wherein the SARM has in-vivo androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor.
41. (Original) The method of claim 26, wherein the SARM is an androgen receptor antagonist.
42. (Original) The method of claim 26, wherein said SARM has an agonistic effect muscle or bone.
43. (Original) The method of claim 26, wherein said SARM has no effect on muscle or bone.
44. (Original) The method of claim 26, wherein said SARM penetrates the central nervous system (CNS).
45. (Original) The method of claim 26, wherein said SARM does not penetrate the central nervous system (CNS).
46. (Original) The method according to claim 26, wherein said administering comprises

administering a pharmaceutical preparation comprising said SARM and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph, prodrug, or any combination thereof; and a pharmaceutically acceptable carrier.

47. (Original) The method according to claim 46, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical preparation in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical preparation; orally administering to said subject said pharmaceutical preparation in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical preparation.

48. (Original) The method according to claim 46 wherein said pharmaceutical preparation is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.

49. (Original) The method of claim 26, wherein said ADIF-associated condition is sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, fatigue, depression, anemia, muscle weakness, hair loss, obesity, polycystic ovarian disease, endometriosis, breast cancer, uterine cancer, ovarian cancer, or any combination thereof.

50. (Original) The method of claim 26, wherein said female subject is an aging female subject.

51. (Withdrawn) A method of treating a female subject suffering from sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, fatigue, depression, anemia, muscle weakness, hair loss, obesity, polycystic ovarian disease, endometriosis, breast cancer, uterine cancer or ovarian cancer due to Androgen Deficiency in Female (ADIF), said method comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound.

52. (Withdrawn) The method of claim 51, wherein said method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of said

SARM compound, or any combination thereof.

53. (Withdrawn) The method according to claim 51, wherein said SARM compound is represented by the structure of formula I:



I

wherein G is O or S;

X is a bond, O, CH_2, NH, Se, PR, NO or NR;

T is OH, OR, -$NHCOCH_3$, or NHCOR

Z is NO_2, CN, COOH, COR, NHCOR or CONHR;

Y is CF_3, F, I, Br, Cl, CN, CR_3 or SnR_3;

Q is alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH; and

R_1 is CH_3, CH_2F, CHF_2, CF_3, CH_2CH_3, or CF_2CF_3.

54. (Withdrawn) The method according to claim 51, wherein said SARM compound is represented by the structure of formula II.



II

wherein X is a bond, O, CH_2, NH, Se, PR, NO or NR;

Z is NO_2, CN, COOH, COR, NHCOR or CONHR;

Y is CF_3, F, I, Br, Cl, CN, CR_3 or SnR_3;

Q is alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH.

55. (Withdrawn) The method according to claim 51, wherein said SARM compound is represented by the structure of formula III.



III

wherein X is a bond, O, CH_2, NH, Se, PR, NO or NR;

G is O or S;

R_1 is CH_3, CH_2F, CHF_2, CF_3, CH_2CH_3, or CF_2CF_3;

T is OH, OR, -$NHCOCH_3$, or NHCOR;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH;

A is a ring selected from:



B is a ring selected from:



wherein A and B cannot simultaneously be a benzene ring;

Z is NO_2, CN, COOH, COR, NHCOR or CONHR;

Y is CF_3, F, I, Br, Cl, CN CR_3 or SnR_3;

Q_1 and Q_2 are independently of each other a hydrogen, alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R, SR,



Q_3 and Q_4 are independently of each other a hydrogen, alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$,

$NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R or SR;

W_1 is O, NH, NR, NO or S; and

W_2 is N or NO.

56. (Withdrawn) The method according to claim 51, wherein said SARM compound is represented by the structure of formula IV:



IV

wherein X is a bond, O, CH_2, NH, Se, PR, NO or NR;

G is O or S;

T is OH, OR, -$NHCOCH_3$, or NHCOR;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH;

R_1 is CH_3, CH_2F, CHF_2, CF_3, CH_2CH_3, or CF_2CF_3;

R_2 is F, Cl, Br, I, CH_3, CF_3, OH, CN, NO_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, alkyl, arylalkyl, OR, NH_2, NHR, NR_2, SR;

R_3 is F, Cl, Br, I, CN, NO_2, COR, COOH, CONHR, CF_3, SnR_3, or R_3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:



Z is NO_2, CN, COR, COOH, or CONHR;

Y is CF_3, F, Br, Cl, I, CN, or SnR_3;

Q is H, alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OH, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

n is an integer of 1-4; and

m is an integer of 1-3.

57. (Withdrawn) The method according to claim 51, wherein said SARM compound is represented by the structure of formula V:



V

wherein

R_2 is F, Cl, Br, I, CH_3, CF_3, OH, CN, NO_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, alkyl, arylalkyl, OR, NH_2, NHR, NR_2, SR;

R_3 is F, Cl, Br, I, CN, NO_2, COR, COOH, CONHR, CF_3, SnR_3, or R_3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:



R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH;

Z is NO_2, CN, COR, COOH, or CONHR;

Y is CF_3, F, Br, Cl, I, CN, or SnR_3;

Q is H, alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OH, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



n is an integer of 1-4; and

m is an integer of 1-3.

58. (Withdrawn) The method according to claim 51, wherein said SARM compound is represented by the structure of formula VI.



VI

59. (Withdrawn) The method according to claim 51, wherein said SARM compound is represented by the structure of formula VII.



VII

60. (Withdrawn) The method according to claim 51, wherein said SARM compound is represented by the structure of formula VIII.



VIII

61. (Withdrawn) The method according to claim 51, wherein said SARM compound is represented by the structure of formula IX.



IX

62. (Withdrawn) The method according to claim 51, wherein said SARM compound is represented by the structure of formula X.



X

63. (Withdrawn) The method according to claim 51, wherein said SARM compound is

represented by the structure of formula XI.



XI

64. (Withdrawn) The method of claim 51, wherein the SARM is an androgen receptor agonist.

65. (Withdrawn) The method of claim 51, wherein the SARM has in-vivo androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor.

66. (Withdrawn) The method of claim 51, wherein the SARM is an androgen receptor antagonist.

67. (Withdrawn) The method of claim 51, wherein said SARM has an agonistic effect muscle or bone.

68. (Withdrawn) The method of claim 51, wherein said SARM has no effect on muscle or bone.

69. (Withdrawn) The method of claim 51, wherein said SARM penetrates the central nervous system (CNS).

70. (Withdrawn) The method of claim 51, wherein said SARM does not penetrate the central nervous system (CNS).

71. (Withdrawn) The method according to claim 51, wherein said administering comprises administering a pharmaceutical preparation comprising said SARM and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph, prodrug, or any combination thereof; and a pharmaceutically acceptable carrier.

72. (Withdrawn) The method according to claim 71, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical preparation in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical preparation; orally administering to said subject said pharmaceutical preparation in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical preparation.

73. (Withdrawn) The method according to claim 71 wherein said pharmaceutical preparation is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.

74. (Withdrawn) The method of claim 51, wherein said ADIF-associated condition is sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, fatigue, depression, anemia, muscle weakness, hair loss, obesity, polycystic ovarian disease, endometriosis, breast cancer, uterine cancer, ovarian cancer, or any combination thereof.

75. (Withdrawn) The method of claim 51, wherein said female subject is an aging female subject.

76. (Withdrawn) A method of preventing, suppressing, inhibiting or reducing the incidence of an Androgen Deficiency in Female (ADIF)-associated condition selected from sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, fatigue, depression, anemia, muscle weakness, hair loss, obesity, polycystic ovarian disease, endometriosis, breast cancer, uterine cancer and ovarian cancer, in a female subject, said method comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound.

77. (Withdrawn) The method of claim 76, wherein said method comprises administering an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph or prodrug of said SARM compound, or any combination thereof.

78. (Withdrawn) The method according to claim 76, wherein said SARM compound is represented by the structure of formula I:



I

wherein G is O or S;

X is a bond, O, CH_2, NH, Se, PR, NO or NR;

T is OH, OR, -$NHCOCH_3$, or NHCOR

Z is NO_2, CN, COOH, COR, NHCOR or CONHR;

Y is CF_3, F, I, Br, Cl, CN, CR_3 or SnR_3;

Q is alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH; and

R_1 is CH_3, CH_2F, CHF_2, CF_3, CH_2CH_3, or CF_2CF_3.

79. (Withdrawn) The method according to claim 76, wherein said SARM compound is represented by the structure of formula II.



II

wherein X is a bond, O, CH_2, NH, Se, PR, NO or NR;

Z is NO_2, CN, COOH, COR, NHCOR or CONHR;

Y is CF_3, F, I, Br, Cl, CN, CR_3 or SnR_3;

Q is alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH.

80. (Withdrawn) The method according to claim 76, wherein said SARM compound is represented by the structure of formula III.



III

wherein X is a bond, O, CH_2, NH, Se, PR, NO or NR;

G is O or S;

R_1 is CH_3, CH_2F, CHF_2, CF_3, CH_2CH_3, or CF_2CF_3;

T is OH, OR, -$NHCOCH_3$, or NHCOR;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH;

A is a ring selected from:



B is a ring selected from:



wherein A and B cannot simultaneously be a benzene ring;

Z is NO_2, CN, COOH, COR, NHCOR or CONHR;

Y is CF_3, F, I, Br, Cl, CN CR_3 or SnR_3;

Q_1 and Q_2 are independently of each other a hydrogen, alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R, SR,



Q_3 and Q_4 are independently of each other a hydrogen, alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$,

$NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OR, COR, OCOR, OSO_2R, SO_2R or SR;

W_1 is O, NH, NR, NO or S; and

W_2 is N or NO.

81. (Withdrawn) The method according to claim 76, wherein said SARM compound is represented by the structure of formula IV:



IV

wherein X is a bond, O, CH_2, NH, Se, PR, NO or NR;

G is O or S;

T is OH, OR, -$NHCOCH_3$, or NHCOR;

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH;

R_1 is CH_3, CH_2F, CHF_2, CF_3, CH_2CH_3, or CF_2CF_3;

R_2 is F, Cl, Br, I, CH_3, CF_3, OH, CN, NO_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, alkyl, arylalkyl, OR, NH_2, NHR, NR_2, SR;

R_3 is F, Cl, Br, I, CN, NO_2, COR, COOH, CONHR, CF_3, SnR_3, or R_3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:



Z is NO_2, CN, COR, COOH, or CONHR;

Y is CF_3, F, Br, Cl, I, CN, or SnR_3;

Q is H, alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OH, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



A B C

n is an integer of 1-4; and

m is an integer of 1-3.

82. (Withdrawn) The method according to claim 76, wherein said SARM compound is represented by the structure of formula V:



V

wherein

R_2 is F, Cl, Br, I, CH_3, CF_3, OH, CN, NO_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, alkyl, arylalkyl, OR, NH_2, NHR, NR_2, SR;

R_3 is F, Cl, Br, I, CN, NO_2, COR, COOH, CONHR, CF_3, SnR_3, or R_3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:



R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH_2F, CHF_2, CF_3, CF_2CF_3, aryl, phenyl, halogen, alkenyl or OH;

Z is NO_2, CN, COR, COOH, or CONHR;

Y is CF_3, F, Br, Cl, I, CN, or SnR_3;

Q is H, alkyl, halogen, CF_3, CN CR_3, SnR_3, NR_2, $NHCOCH_3$, $NHCOCF_3$, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, $NHCSCH_3$, $NHCSCF_3$, NHCSR $NHSO_2CH_3$, $NHSO_2R$, OH, OR, COR, OCOR, OSO_2R, SO_2R, SR; or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:



n is an integer of 1-4; and

m is an integer of 1-3.

83. (Withdrawn) The method according to claim 76, wherein said SARM compound is represented by the structure of formula VI.



VI

84. (Withdrawn) The method according to claim 76, wherein said SARM compound is represented by the structure of formula VII.



VII

85. (Withdrawn) The method according to claim 76, wherein said SARM compound is represented by the structure of formula VIII.



VIII

86. (Withdrawn) The method according to claim 76, wherein said SARM compound is represented by the structure of formula IX.



IX

87. (Withdrawn) The method according to claim 76, wherein said SARM compound is represented by the structure of formula X.



X

88. (Withdrawn) The method according to claim 76, wherein said SARM compound is

represented by the structure of formula XI.



XI

89. (Withdrawn) The method of claim 76, wherein the SARM is an androgen receptor agonist.

90. (Withdrawn) The method of claim 76, wherein the SARM has in-vivo androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor.

91. (Withdrawn) The method of claim 76, wherein the SARM is an androgen receptor antagonist.

92. (Withdrawn) The method of claim 76, wherein said SARM has an agonistic effect muscle or bone.

93. (Withdrawn) The method of claim 76, wherein said SARM has no effect on muscle or bone.

94. (Withdrawn) The method of claim 76, wherein said SARM penetrates the central nervous system (CNS).

95. (Withdrawn) The method of claim 70, wherein said SARM does not penetrate the central nervous system (CNS).

96. (Withdrawn) The method according to claim 76, wherein said administering comprises administering a pharmaceutical preparation comprising said SARM and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph, prodrug, or any combination thereof; and a pharmaceutically acceptable carrier.

97. (Withdrawn) The method according to claim 96, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical preparation in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical preparation; orally administering to said subject said pharmaceutical preparation in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical preparation.

98. (Withdrawn) The method according to claim 96 wherein said pharmaceutical preparation is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.

99. (Withdrawn) The method of claim 76, wherein said ADIF-associated condition is sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, fatigue, depression, anemia, muscle weakness, hair loss, obesity, polycystic ovarian disease, endometriosis, breast cancer, uterine cancer, ovarian cancer, or any combination thereof.

The method of claim 76, wherein said female subject is an aging female subject.

Applicants elect with traverse to prosecute claims 26-50 of Group II drawn to suppressing, inhibiting, preventing and reducing the incidence of an Androgen Deficiency in Female (ADIF)-associated condition via the administration of a SARM. Claims 1-8, 14-25 of group I, 51-75 of group III, and 76-100 are withdrawn at this time.

Applicants note that the four groups are related Applications. Applicants submit that searches for any one group will uncover results for the others, thus the inventions are related and not distinct as alleged. Moreover, MPEP 803 notes that "if the search and examination of an entire application can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to independent or distinct inventions." Applicants maintain that such search does not pose a serious burden, in particular due to the relatedness of the claims at issue.

The Examiner noted claims 26-50 to be generic and required a species election. Applicants maintain that there is no undue burden of search for the Examiner regarding the various species of SARMs claimed for use, and request withdrawal of the requirement for species election.

Applicants elect a compound of formula I. Applicants understand that their election of single species is being made solely to, facilitate examination of the claims. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 81.141.

Applicants reserve all rights in these non-elected claims to file divisional and/or continuation patent applications.

If the Examiner has any questions or comments as to this response, the undersigned may be contacted at the address and telephone number below.

Please charge any fees associated with this paper to deposit account No. 50-3355.

Respectfully submitted,

Mark S. Cohen
Attorney/Agent for Applicant(s)
Registration No. 42,425

Dated: June 9, 2006

Pearl Cohen Zedek Latzer, LLP
1500 Broadway, 12th Floor
New York, New York 10036
Tel: (646) 878-0800
Fax: (646) 878-0801